NATCOPHARM IN EQUITY
loading…—
Day range—
52-week range—
Market cap—
P/E · TTM—
As of—
| CUSTOMER | BASIS | EST ₹CR | RANGE | % REV | BUCKET | PERIOD | METHOD | CONF |
|---|---|---|---|---|---|---|---|---|
| Business | REV SHARE | 3,670 | 3,670–3,670 | 90.0% | — | FY26 | DISC | 90% |
| “Details of business activities (accounting for 90% of the turnover): S. No. Description of Main Activity Description of Business Activity % of Turnover of the …” AR · +2 DOC | ||||||||
| United States | REV SHARE | 3,482 | 3,482–3,482 | 78.6% | — | FY25 | DISC | 90% |
| “Our international business, particularly export formulations, generated H 37,597 Million, accounting for 78.6% of total revenue, driven by strong growth in reg…” AR · +2 DOC | ||||||||
| Others | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “Less: Allowance for doubtful advances (171) (193) 836 912 (Unsecured, considered good) Prepaid expenses 305 289 Export incentives 17 26 Balance with statutory …” AR · +1 DOC | ||||||||
| United States | UNSTATED | — | — | — | COGS | FY26 | EST | 75% |
| “Total pharmaceutical exports neared the $30.5 billion threshold, with approximately 50% of shipments directed to highly regulated markets like the United State…” AR DOC | ||||||||
| Business | UNSTATED | — | — | — | COGS | FY25 | EST | 75% |
| “Revenue from our different segments (in %) Export Formulations 78.6 8.4 4.2 1.3 7.5 Domestic Pharmaceuticals Business Active Pharmaceutical Ingredient Crop Hea…” AR · +1 DOC | ||||||||
| Others | UNSTATED | — | — | — | COGS | FY25 | EST | 75% |
| “Revenue from our different segments (in %) Export Formulations 78.6 8.4 4.2 1.3 7.5 Domestic Pharmaceuticals Business Active Pharmaceutical Ingredient Crop Hea…” AR DOC | ||||||||
| Securities and Exchange Board of India | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “(not applicable to the Company during the audit period) (f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regul…” AR · +1 DOC | ||||||||
| Financial Year | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE COURTS/REGULATORS During Financial year 2024-25, there were no significant and/or material orders, passed by any …” AR · +1 DOC | ||||||||
| China. | UNSTATED | — | — | — | — | 2025-11 | EST | 65% |
| “We are selling in China, which is good, and we have a reasonable ROW business.” CONCALL DOC | ||||||||
| CDSLCentral Depository Services (India) Ltd. | UNSTATED | — | — | — | — | FY26 | EST | 60% |
| “The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in p…” AR · +1 DOC | ||||||||
| BSEBSE Ltd. | UNSTATED | — | — | — | SG&A | FY25 | EST | 60% |
| “Any price sensitive information is brought to the notice of both the Stock Exchanges (NSE and BSE), Press and Electronic Media in order to avoid any possible i…” AR DOC | ||||||||
| SUPPLIER | BASIS | EST ₹CR | RANGE | % COST | BUCKET | PERIOD | METHOD | CONF |
|---|---|---|---|---|---|---|---|---|
| Others | UNSTATED | — | — | — | — | FY25 | EST | 70% |
| “Trade payables Ageing of trade payables as at 31-03-2025 Outstanding for following periods from due date of payment MSME Others Disputed dues -MSME Disputed du…” AR DOC | ||||||||
| SOURCE | READ | % | LAST READ |
|---|---|---|---|
| ANNUAL | 2/2 | 100% | 15-OCT-26 |
| CONCALL | 4/4 | 100% | 15-OCT-26 |
| RATINGS | 0/1 | 0% | — |
| SCREENER | 1/1 | 100% | 10-NOV-26 |
| SIGNAL | VALUE | AS OF | INPUTS |
|---|---|---|---|
| CUST MOM 1M | +13.4% | 14-NOV-26 | from 15-OCT-26 · Central Depository Services (India) Ltd. +11.9% w 1 · BSE Ltd. +14.9% w 1 |